Vertex Pharmaceuticals (VRTX) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $612.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna. According to TipRanks, Flynn has an average return of 9.8% and a 56.21% success rate on recommended stocks.
In addition to Morgan Stanley, Vertex Pharmaceuticals also received a Buy from RBC Capital’s Brian Abrahams in a report issued on April 7. However, on April 2, Erste Group maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.23 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $2.91 billion and had a net profit of $913 million
Read More on VRTX:
Disclaimer & DisclosureReport an Issue
- Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
- Halozyme enters global global collaboration and license agreement with Vertex
- Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
- Vertex announces U.S. FDA approval for label extensions of Alyftrek, Trikafta
- Vertex Advances FDA Filing for IgA Nephropathy Therapy
